Emma Wormsley
Chief Executive Officer
Replay available
GSK plc (GSK) Q2 2025 Earnings Call
GSK plc (NYSE: GSK) Q2 2025 earnings conference call, held 2025-07-30. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Tony Wood
Chief Scientific Officer
Luke Miles
President, Pharmaceuticals
Deborah Waterhouse
Head of HIV
Julie Brown
Chief Financial Officer
David Redfern
Head of Investor Relations
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Gsk Plc.
Replay transcript excerpt
WEBVTT 00:00:01.120 -- 00:00:06.480 Ladies and gentlemen, a very warm welcome to the GSK Q2 2025 00:00:06.480 -- 00:00:12.100 results call. I'm delighted to be joined today by Emma Wormsley, Tony Wood, 00:00:12.100 -- 00:00:18.060 Luke Miles, Deborah Waterhouse and Julie Brown, with David Redfern joining for Q&A. 00:00:18.060 -- 00:00:22.480 Today's call will last approximately one hour, with the presentation taking around 30 00:00:22.480 -- 00:00:24.980 minutes and the remaining time for your questions. 00:00:24.980 -- 00:00:30.420 Please ask only one to two questions so that everyone has a chance to participate. 00:00:30.420 -- 00:00:34.180 Before we start, please turn to slide three. 00:00:34.340 -- 00:00:39.240 This is the usual safe harbour statement. We will comment on our performance using constant 00:00:39.240 -- 00:00:43.080 exchange rates or CR, unless otherwise stated. 00:00:43.080 -- 00:00:47.140 I will now hand over to Emma on slide four. 00:00:47.140 -- 00:00:50.600 Thank you and welcome to everybody joining us today. 00:00:50.600 -- 00:00:55.940 Please turn to the next slide. Our second quarter results once again 00:00:55.940 -- 00:01:01.160 demonstrate GSK's strong performance momentum and the quality and strength 00:01:01.160 -- 00:01:03.220 of our portfolio. 00:01:03.220 -- 00:01:08.240 Group sales were up 6% for the quarter, core operating profit was up 12% and core earnings 00:01:08.240 -- 00:01:13.560 per share grew 15% to 46.5 pence. Sales 00:01:13.560 -- 00:01:18.600 growth was driven by our largest business, Specialty Medicines, up 15% 00:01:18.600 -- 00:01:23.340 and vaccine sales also contributed with sales up 9% in the quarter. 00:01:23.340 -- 00:01:28.240 This led to increases in profits and earnings, which also benefited from a strong foc...